No Data
Cautious Optimism Amidst Growth Deceleration and Rising Competition for Biogen
US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
Jones Research Starts Larimar at Buy, Cites Lead Asset Nomlabofusp
Healthcare Stocks Have Popped. Consider These 2 That Haven't. -- Barrons.com
Biogen Names Lloyd Minor, Menelas Pangalos to Board >BIIB
Express News | Biogen Board Appoints Two New Independent Directors
webguybob : The Etsy downgrade surprised me!
105535782 : ok
102242135 Lim : K